FAQ // MOTS-C
MOTS-c peptide: frequently asked questions, answered from the evidence
Direct answers drawn from the published literature and the audited regulatory record — cited where the claim is quantitative, and honest where the human data does not exist.
What are the potential benefits of MOTS-c?
In animal and cell studies MOTS-c activates AMPK, improves insulin sensitivity, prevents diet-induced obesity, and enhances physical capacity in aged mice [1][2]. Human evidence is observational biomarker data, not interventional outcomes [4]. So the reported benefits describe research findings in their stated species, not demonstrated effects of taking MOTS-c in people.
Are circulating MOTS-c levels a biomarker of health or aging?
Circulating and tissue MOTS-c change with age and metabolic state, and in a chronic-hemodialysis cohort serum MOTS-c was independently associated with mortality and cardiovascular events, supporting interest in it as a human biomarker [9][12]. It is an association in defined groups, not proof that altering MOTS-c changes outcomes.
What does the MOTS-c peptide do?
MOTS-c is a 16-amino-acid mitochondrial-derived peptide that inhibits the folate cycle to activate AMPK and, under stress, translocates to the nucleus to regulate gene expression [1][3]. Its best-characterized effects are on glucose handling and skeletal muscle in animal models [1]. In 2024, casein kinase 2 (CK2) was identified as a direct binding target [5].
What are the negative side effects of MOTS-c?
No completed human safety trial of exogenous MOTS-c has been published, so a human side-effect profile is not established [4]. All dosing figures come from rodent research and cannot be read as human safety data. As an unapproved research chemical, product purity and sterility also vary by supplier [4].
Is MOTS-c legal to buy?
MOTS-c is not an FDA-approved drug and is sold only as a research chemical for laboratory use; it has no approved human indication or formulation [4]. See the MOTS-c legal status page, which also covers the FDA 503A compounding framework and MOTS-c's place on the July 2026 PCAC evaluation agenda.
How often do you inject MOTS-c?
There is no human dosing schedule. Published rodent studies used daily or thrice-weekly intraperitoneal injection — for example 15 mg/kg/day or 15 mg/kg three times weekly [2] — which is animal-model methodology, not human guidance [4].
Can MOTS-c cause weight gain?
The animal literature reports the opposite direction of effect: MOTS-c prevented diet-induced obesity and increased adipose thermogenesis in mice [1]. There are no human data describing weight change from exogenous MOTS-c [4].
Is MOTS-c hard on the liver?
No human hepatic-safety data exist for exogenous MOTS-c, so the question cannot be answered from the published evidence, which is preclinical and observational [4]. The literature does not characterize liver effects in people.
What are the downsides of MOTS-c?
The main downsides are evidentiary and regulatory: no completed human efficacy or safety trials, no validated human pharmacokinetics, an unregulated research-chemical supply, and anti-doping prohibition for athletes [4]. A pro-diabetogenic mitochondrial variant (m.1382A>C) also suggests effects are not uniform across populations [8].
Can I get MOTS-c over the counter?
MOTS-c is not an approved drug or dietary supplement and is not sold over the counter as a consumer product; it is distributed only for laboratory research [4]. See the MOTS-c legal status page for the full regulatory picture.
How long does it take for MOTS-c to kick in?
No human onset timeline is established [4]. Effects in animal studies are reported over repeated dosing rather than as an immediate result [2]. There is no validated human pharmacokinetic profile to define an onset.
Where is best to inject MOTS-c?
The dominant route in published work is intraperitoneal injection in rodents [2]. There is no validated human injection site or protocol, so this describes research methodology rather than human guidance [4].
How does MOTS-c make you feel?
There is no human subjective-effect data for exogenous MOTS-c [4]. The published evidence describes molecular, metabolic, and physical-capacity outcomes in animals [1][2], not a human experience.
How long does MOTS-c take to work?
Animal studies report metabolic and performance changes over repeated daily or thrice-weekly dosing rather than a defined onset [2]. No validated human timeline exists [4].
Does MOTS-c burn fat?
In mice, MOTS-c prevented diet-induced obesity and increased adipose thermogenic activation [1], but these are animal-model findings. No human study demonstrates fat-burning from exogenous MOTS-c [4].
Can I inject MOTS-c every day?
Some rodent studies used daily intraperitoneal dosing [1][2], but there is no human dosing schedule and no clinical recommendation for frequency or duration of use [4].
How long should you take MOTS-c?
No validated human duration exists. Published regimens range from roughly one week to several weeks in animals [1][2] and are study-specific methodology, not human protocols [4].
Is MOTS-c bad for the liver?
There is no human hepatic-safety evidence for exogenous MOTS-c; the published literature does not characterize liver effects in people [4]. The evidence base is preclinical and observational.
What are the top peptides for muscle growth?
MOTS-c is studied for muscle preservation and exercise-mimetic effects rather than muscle building in healthy subjects; the literature reports reduced atrophy signaling in animals, not hypertrophy [2][5]. This digest does not rank or recommend peptides.
What should you not mix with peptides?
No human drug-interaction studies of MOTS-c exist, so interaction guidance cannot be given; the question is unanswerable from the published evidence [4]. Any claim otherwise is not supported by the literature for this peptide.
Is MOTS-c legal?
MOTS-c is not an FDA-approved drug and is sold for research use only [4]. See the MOTS-c legal status page, which summarizes the FDA 503A framework and MOTS-c's listing on the July 2026 PCAC evaluation agenda from the audited regulatory record.
Can you get MOTS-c from a compounding pharmacy?
Compounded access to peptides is governed by the FDA 503A bulk-drug-substance framework, and MOTS-c is currently a substance under FDA evaluation rather than one on the bulks list, so that eligibility is unresolved [4]. See the FDA 503A compounding framework for the full explanation.
What is the FDA 503A status of MOTS-c?
MOTS-c is not FDA-approved, and the audited reference does not assign it a 503A category; it is named on the FDA's July 2026 PCAC agenda as a substance being considered for the 503A bulks list — a scheduled evaluation, not a listing decision [4]. See the MOTS-c legal status page.